PTC Therapeutics officer sells shares after exercises
PTC Therapeutics chief technical operations officer Neil Gregory Almstead sold 46,774 shares of common stock in open-market trades while exercising stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PTC Therapeutics chief technical operations officer Neil Gregory Almstead sold 46,774 shares of common stock in open-market trades while exercising stock options. The sales on July 6–7 were executed under a pre-set Rule 10b5-1 trading plan.
Almstead exercised options to acquire 46,774 shares at exercise prices of $38.10 and $39.42 per share, then sold equivalent amounts at weighted average prices in the mid‑$80s to high‑$80s. Following these transactions, he holds 60,299 shares directly and 2,899 shares indirectly through his spouse.
Insider Trade Summary 10b5-1
Exercise and Sale: 46,774 shares ($2.28M approx. pre-tax spread)
Exercise and Sale
17 txns
Insider
Almstead Neil Gregory
Role
CHIEF TECHNICAL OPS OFFICER
Sold
46,774 shs ($4.09M)
Approx. gross sale proceeds
$4.09M
Approx. exercise cost
$1.82M
Approx. pre-tax spread
$2.28M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 24,613 | $0.00 | $0.00 |
| Exercise | Common Stock | 24,613 | $39.42 | $970K |
| Sale | Common Stock | 3,956 | $87.17 | $345K |
| Sale | Common Stock | 11,369 | $89.03 | $1.01M |
| Sale | Common Stock | 9,288 | $89.44 | $831K |
| Exercise | Stock Option (Right to Buy) | 811 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 18,876 | $0.00 | $0.00 |
| Exercise | Stock Option (Right to Buy) | 2,474 | $0.00 | $0.00 |
| Exercise | Common Stock | 811 | $38.10 | $31K |
| Sale | Common Stock | 426 | $85.28 | $36K |
| Sale | Common Stock | 385 | $86.34 | $33K |
| Exercise | Common Stock | 18,876 | $38.10 | $719K |
| Sale | Common Stock | 8,786 | $85.35 | $750K |
| Sale | Common Stock | 10,090 | $86.32 | $871K |
| Exercise | Common Stock | 2,474 | $39.42 | $98K |
| Sale | Common Stock | 2,474 | $87.03 | $215K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,063 contracts (Direct);
Common Stock — 60,299 shares (Direct);
Common Stock — 2,899 shares (Indirect, By Spouse)
Footnotes (12)
- F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
- F2. Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026.
- F3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.95 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.02 to $86.73 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $85.00 to $85.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $86.03 to $86.74 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $87.00 to $87.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F8. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $87.00 to $87.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F9. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $88.29 to $89.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F10. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $89.29 to $89.75 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F11. Currently exercisable.
- F12. This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.
Key Figures
Shares sold: 46,774 shares
Shares exercised: 46,774 shares
Exercise price 1: $39.42 per share
+5 more
8 metrics
Shares sold
46,774 shares
Net open-market sales reported on July 6–7, 2026
Shares exercised
46,774 shares
Common stock acquired via option exercises (codes M)
Exercise price 1
$39.42 per share
Stock option conversion_or_exercise_price on certain grants
Exercise price 2
$38.10 per share
Stock option conversion_or_exercise_price on other grants
Direct holdings after
60,299 shares
Total common stock directly owned following transactions
Indirect holdings after
2,899 shares
Common stock held indirectly through spouse as of July 6, 2026
Highest listed sale price
$89.44 per share
One reported weighted average price for an open-market sale block
Net buy/sell direction
Net-sell of 46,774 shares
Form 4 transactionSummary netBuySellShares and direction
Key Terms
Rule 10b5-1 plan, weighted average price, employee stock purchase plan, Stock Option (Right to Buy), +1 more
5 terms
Rule 10b5-1 plan regulatory
"This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
weighted average price financial
"This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
employee stock purchase plan financial
"Includes 162 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy) with underlying common stock shares exercisable at set prices."
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion describing option exercises into common stock."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did PTC Therapeutics (PTCT) executive Neil Almstead report in this Form 4?
Neil Almstead reported option exercises and related share sales totaling 46,774 PTCT shares. He exercised stock options at $38.10 and $39.42 per share, then sold equivalent shares in open-market trades under a pre-set Rule 10b5-1 trading plan.
What stock options did Neil Almstead exercise in PTC Therapeutics (PTCT)?
Almstead exercised stock options covering 46,774 PTCT shares. The underlying options had exercise prices of $38.10 and $39.42 per share, converting derivative positions into common stock that was then sold in open-market transactions disclosed in the Form 4.
Does Neil Almstead participate in PTC Therapeutics (PTCT) employee stock purchase programs?
Yes. A footnote notes that Almstead’s holdings include 162 PTCT common shares acquired under the company’s employee stock purchase plan for the period ended June 30, 2026, showing additional share accumulation through company-sponsored equity programs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
